Related Experiment Videos
Risk of proarrhythmia with class III antiarrhythmic agents: sex-based differences and other issues
1Department of Medicine, The Milton S. Hershey Medical Center, Penn State University College of Medicine, Hershey, Pennsylvania 17033, USA.
Insights
Women with atrial fibrillation face worse prognoses and a higher risk of torsades de pointes, especially with heart failure. Careful monitoring and management are crucial for reducing proarrhythmia risks in these patients.
Area of Science:
- Cardiology
- Electrophysiology
- Pharmacology
Background:
- Women with atrial fibrillation have a worse prognosis than men, despite men having a higher incidence.
- Congestive heart failure exacerbates atrial fibrillation risk and prognosis more significantly in women than men.
- Women exhibit a longer baseline corrected QT interval, potentially due to hormonal influences.
Purpose of the Study:
- To examine the increased risk of torsades de pointes in women treated with Class III antiarrhythmic drugs.
- To highlight the importance of managing risk factors for proarrhythmia in women with atrial fibrillation.
Main Methods:
- Review of existing literature on atrial fibrillation, QT interval, torsades de pointes, and antiarrhythmic drug use in men and women.
- Analysis of risk factors, including congestive heart failure and potassium-affecting medications.
Main Results:
- Female sex is independently associated with an increased risk of torsades de pointes with potassium antagonists.
- All Class III antiarrhythmic drugs show a higher prevalence of torsades de pointes in women compared to men.
- Congestive heart failure and polypharmacy increase proarrhythmia risk, particularly in women.
Conclusions:
- Women with atrial fibrillation require careful monitoring of QT interval and potassium levels.
- Management strategies should focus on controlling heart failure and avoiding polypharmacy with potassium antagonists.
- Particular vigilance is needed for women with additional risk factors for torsades de pointes when using Class III antiarrhythmic agents.
Abstract:
Although men have a higher risk of atrial fibrillation compared with women, the absolute number of women with atrial fibrillation is greater. Congestive heart failure increases the risk of developing atrial fibrillation in women more than in men, and the prognosis for women with atrial fibrillation is worse than for men. The longer baseline corrected QT interval in women is well known. The mechanism is likely the result of increased circulating androgens, causing the QT interval to shorten in men after puberty. Female sex is associated with an increased risk of torsades de pointes in the setting of potassium antagonists. Class III antiarrhythmic drugs are frequently used for the treatment of atrial fibrillation in heart failure patients because of their neutral effect on mortality and their tolerance by patients with low ejection fractions. Although amiodarone and azimilide carry a low potential for producing torsades de pointes compared with sotalol and dofetilide, the prevalence of torsades de pointes in women is at least twice that in men for all these drugs. Careful monitoring of the QT interval and potassium level, as well as control of congestive heart failure, can help reduce the risk of proarrhythmia. Avoidance of polypharmacy with other potassium antagonists and unmonitored drug formulation changes are important in the management of all patients taking class III agents, but they are particularly crucial in women with additional risk factors for torsades de pointes.